Randomized trial of peginterferon alfa‐2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response

Maria Buti, Yoav Lurie, Natalia G. Zakharova, Natalia P. Blokhina, Andrzej Horban, Gerlinde Teuber, Christoph Sarrazin, Ligita Balciuniene, Saya V. Feinman, Rab Faruqi, Lisa D. Pedicone, Rafael Esteban, for the SUCCESS Study Investigators – 30 June 2010 – The benefit of extending treatment duration with peginterferon (PEG‐IFN) and ribavirin (RBV) from 48 weeks to 72 weeks for patients with chronic hepatitis C genotype 1 infection has not been well established.

I148M patatin‐like phospholipase domain‐containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease

Luca Valenti, Anna Alisi, Enrico Galmozzi, Andrea Bartuli, Benedetta Del Menico, Arianna Alterio, Paola Dongiovanni, Silvia Fargion, Valerio Nobili – 30 June 2010 – Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease in children. Genetic variability, which is a main player in NAFLD, is especially characterized by polymorphisms in genes involved in the development and progression of the disease to nonalcoholic steatohepatitis (NASH).

Virologic response rates of weight‐based taribavirin versus ribavirin in treatment‐naive patients with genotype 1 chronic hepatitis C

Fred Poordad, Eric Lawitz, Mitchell L. Shiffman, Tarek Hassanein, Andrew J. Muir, Bruce R. Bacon, Jamie Heise, Deanine Halliman, Eric Chun, Janet Hammond – 30 June 2010 – Ribavirin‐induced hemolytic anemia can prompt dose reductions and lower sustained virologic response (SVR) rates in the treatment of patients with chronic hepatitis C. The study aimed to determine if weight‐based dosing of taribavirin (TBV), an oral prodrug of ribavirin (RBV), demonstrated efficacy comparable to RBV while maintaining its previously demonstrated anemia advantage with fixed dose administration. A U.S.

Defective bone morphogenic protein signaling underlies hepcidin deficiency in HFE hereditary hemochromatosis

John D. Ryan, Eleanor Ryan, Aurelie Fabre, Matthew W. Lawless, John Crowe – 30 June 2010 – Hereditary hemochromatosis (HH) is a common inherited iron overload disorder. The vast majority of patients carry the missense Cys282Tyr mutation of the HFE gene. Hepcidin, the central regulator of iron homeostasis, is deficient in HH, leading to unchecked iron absorption and subsequent iron overload. The bone morphogenic protein (BMP)/small mothers against decapentaplegic (Smad) signaling cascade is central to the regulation of hepcidin.

Liver grafts contain a unique subset of natural killer cells that are transferred into the recipient after liver transplantation

Viviana Moroso, Herold J. Metselaar, Shanta Mancham, Hugo W. Tilanus, Diana Eissens, Arnold van der Meer, Luc J. W. van der Laan, Ernst J. Kuipers, Irma Joosten, Jaap Kwekkeboom – 25 June 2010 – In contrast to other solid organ transplantations, liver grafts have tolerogenic properties. Animal models indicate that donor leukocytes transferred into the recipient after liver transplantation (LTX) play a relevant role in this tolerogenic phenomenon. However, the specific donor cell types involved in modulation of the recipient alloresponse are not yet defined.

Subscribe to